Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vinflunine combinations in cisplatin-ineligible advanced urothelial carcinoma
NL-OMON36397Phase 2Withdrawn
- Sponsor
- Pierre Fabre Laboratories
- Start
- Mar 2011
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in transitional cell carcinoma (TCC) and bladder cancer comparing Vinflunine + Gemcitabine with Vinflunine + Carboplatin (2 arms). Primary endpoint: Disease control rate. Planned start Mar 2011; status: withdrawn.
02
Drugs
vinfluninegemcitabinecarboplatin
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on NL-OMON36397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36397.